Navigation Links
FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
Date:3/9/2011

NEW YORK, March 9, 2011 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations welcome the U.S. Food and Drug Administration's (FDA) historic approval of BENLYSTA® (belimumab) for systemic lupus erythematosus (lupus), launching the first safe and effective treatment for lupus in more than half a century.

"This is a moment of enormous relief for people with lupus, and a landmark achievement for the nation's scientists, doctors and industry investigators searching for new answers to lupus," said Margaret G. Dowd, president of the Lupus Research Institute, an organization uniquely dedicated to pioneering discovery through novel research in lupus. "BENLYSTA's winding path to FDA approval is a triumph for the dedicated pursuit of innovative science and smart trial design in achieving solid results in the complex autoimmune disease of lupus."

The FDA announced today that BENLYSTA, developed by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK), is approved for treatment of people with active systemic lupus. This decision followed its Arthritis Advisory Committee's 13-2 vote on November 16, 2010 to recommend the drug's approval.  

The development of BENLYSTA stems from the scientific discovery of a new immune system molecule, BLyS, which revealed a critical new pathway that can be manipulated to treat lupus.  BENLYSTA is founded on novel, fundamental science from industry and academia that explores a range of disease pathways and mechanisms, much like the studies that the LRI has been supporting for a decade.

"With BENLYSTA, physicians can now prescribe an effective new agent to manage the signs and symptoms of lupus, and improve the quality of life of their patients," said David S. Pisetsky, M.D., Ph.D., Professor of Medicine and Immunology at Duke University Medical Center and a member of the LRI Scientific Advisory Board.  

"Furthermore, the approval provides important lessons for the lupus research field," said Dr. Pisetsky. "The trial design of the BENLYSTA studies, including the use of a composite outcome measure to assess efficacy, is a major innovation. The developers have taken a new pathway for drug research in lupus, which hopefully, will encourage other companies to rededicate themselves to innovation to reduce and eventually wipe out the burden of this serious autoimmune disease."

"The approval of BENLYSTA means good news for patients like me, hopefully reducing the seemingly endless number of medications with harsh side effects we need to take to stay alive," said Sabrina Nixon, an author and single mother of two from Chicago who was diagnosed with lupus in 2004.

"We thank the hundreds of people with lupus who enrolled and took part in these important BENLYSTA trials," said Dowd. The LRI assists in educating people with lupus about participating in clinical trials to bring safe and effective treatments to market.  To learn more, visit www.LupusTrials.org.

About Lupus

Lupus—systemic lupus erythematosus—is a chronic and often disabling autoimmune disease that is estimated to affect more than 1.5 million Americans.  Ninety percent of people living with lupus are women, with the majority being of childbearing age. People with lupus suffer from symptoms including fever, intense fatigue and exhaustion, joint pains, cognitive problems and skin rashes.  No two cases of lupus are alike, and the effects of the disease can range from kidney disease, premature heart disease, stroke or lung inflammation. There is no known cause or cure for lupus, and no new treatments have been approved for lupus in over 50 years.  For some patients, current treatments can often be toxic and more damaging than the disease itself.

About the Lupus Research Institute

The Lupus Research Institute (LRI) is the nation's only nonprofit organization solely dedicated to novel research in lupus, with the belief that innovative research is the key to finding safer and more effective treatments and a cure for lupus.  In late 1999, as 1.5 million Americans faced the pain and devastation of lupus, patients, families and the nation's leading researchers came together to establish the LRI. With a bold approach and rigorous standards, such as funding innovative research approaches, recruiting new scientists to the field and driving translation of science into the clinic, the LRI is making the breakthroughs that spell compelling new hope for patients worldwide who suffer from this devastating autoimmune illness.

Click here to learn more about the Lupus Research Institute.  


'/>"/>
SOURCE Lupus Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United ... year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and ... havens have extremely low property-tax rates, which contributes to the relatively lower cost ...
Breaking Medicine News(10 mins):